ScienceTechyNews: ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

12:51 PM
University of Colorado Cancer Center study presented at ASCO 2019 shows that brigatinib remains effective even after treatment with another next-generation ALK inhibitor

by

Post a Comment

No comments

Subscribe to: Post Comments ( Atom )
Powered by Blogger.